Introducing Kardia 12L: The first of its kind 12-lead portable ECG | Learn More

AliveCor Logo

Our Products

AFib Screening
Data Integration Solutions
KardiaCare Plus
KardiaComplete
Kardia 12L

New

KardiaMobile 6L
AliveCor K1000
KardiaStation
KardiaPro
Kardia ECG Devices

Our Solutions

Health Systems
Clinical Trials
Payors
Employers
OEMs
Veterans Affairs

About

Leadership
Mission
Clinical Research
Our AI
For Consumers
The Human Component Film
Newsroom
(855) 338-8800
AliveCor Logo
AliveCor Logo
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
    • (855) 338-8800
    • Mission
    • Careers
    • Research
    • Newsroom
    • FAQs
    • User Manuals
    • Compatibility
    • Shipping
    • (855) 338-8800
    • KardiaMobile Card
    • KardiaMobile 6L
    • KardiaMobile
    • KardiaCare
    • International
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • Privacy Policy
  • Security
  • Telehealth Informed Consent
  • Terms
  • Accessibility

©2024 AliveCor, Inc. All Rights Reserved. Patents www.alivecor.com/patents. AliveCor and Kardia are trademarks of AliveCor, Inc. in the United States and other countries. Apple is a trademark of Apple, Inc. registered in the U.S. and other countries. App Store is a service mark of Apple, Inc. Android is a trademark of Google Inc. Google Play is a trademark of Google Inc.

Patient-Centric AFib Screening

Early detection of arrhythmias is possible with Kardia screening program, a home-based screening program that is easy for at-risk members to follow, for short or long-term monitoring.

AFib Prevalence is significantly undetected

40%

of AFib patients are asymptomatic

20%

of patients’ first clinical manifestation of AFib is stroke²

$8.7k

AFib can increase annual health care costs by $8700 per patient³

KardiaMobile®

Proven to detect undiagnosed AFib & reduce total cost of care⁴

check-icon#1 patient-preferred personal ECG brand with high satisfaction
check-iconEasy to use for long-term monitoring with no uncomfortable patches or wires
check-iconFDA-cleared, instant heart rhythm determination gives patients peace of mind
check-iconTelecardiology coverage nationwide with same-day appointments available

KardiaMobile® detected more AFib than routine care

REHEARSE-AF Study found a nearly 4x increase in AFib detection in KardiaMobile group compared to routine care alone.⁴

  • RCT (n=1001) using KardiaMobile for AFib screening
  • Patients aged ≥ 65 with CHADS-VASc score ≥ 2
  • ECGs captured 2x weekly over 12 months (or if symptomatic)

How It Works

masolutions.step1.title

Step 1

At-risk members enroll in program and receive KardiaMobile ECG device for real-time monitoring.

masolutions.step2.title

Step 2

If possible arrhythmia detected, AliveCor cardiac tech reviews ECG within 24 hrs and sends to cardiologist for confirmation.

masolutions.step3.title

Step 3

Member receives virtual visit with AliveCor-affiliated cardiologist to make an appropriate diagnosis, with guidance to appropriate health plan resources.

Offer an innovative supplemental benefit program designed to improve risk adjustment accuracy and support quality initiatives

References
  1. Boriani, et al. "Asymptomatic Atrial Fibrillation: Clinical Correlates, Management, and Outcomes in the EORP-AF Pilot General Registry." Am J Med vol. 128,5 (2015): 509-518.2.
  2. Tayal, A Het al. "Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke." Neurology vol. 71,21 (2008): 1696-701.
  3. Calkins, Het al. "HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation." Heart Rhythm vol. 14, 10 (2017): e275-444.
  4. Halcox, J P Jet al. "Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study." Circulation vol. 136,19 (2017): 1784-1794.